Century Therapeutics (IPSC) Registration Filing summary

Company overview and business model

• Focuses on allogeneic pluripotent stem cell therapies for autoimmune diseases and cancer, leveraging induced pluripotent stem cells (iPSCs) for scalable, off-the-shelf cell therapies.

• Utilizes proprietary technologies including CRISPR gene editing, Allo-Evasion™ for immune evasion, and advanced manufacturing for cost and scale advantages.

• Pipeline includes NK, T cell, and beta islet programs, with lead candidates targeting type 1 diabetes and B-cell-mediated diseases.

• Announced prioritization of CNTY-101 for B-cell-mediated autoimmune diseases and initiation of IND-enabling studies for CNTY-813 and CNTY-308, with clinical studies expected in 2026.

Financial performance and metrics

• Raised approximately $135 million in gross proceeds from a private placement in January 2026, with net proceeds of $126.7 million after expenses.

• As of February 2, 2026, had 179,647,829 shares of common stock outstanding.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; will receive proceeds only from cash exercise of warrants.

• Proceeds from warrant exercises will be used for development of lead product CNTY-813, working capital, and general corporate purposes.